Description
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 10 bp deletion in exon3 and 1 bp deletion in exon3 and 1 bp insertion in exon3.,
Disease:Adenocarcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-GNPAT, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
GNPAT also known as glyceronephosphate O-acyltransferase or dihydroxyacetone phosphate acyltransferase (DAPAT) is an enzyme that plays an important role in lipid metabolism. The enzyme has a mass of approximately 73 kDa. It is expressed mainly in peroxisomes organelles involved in various metabolic functions. The enzyme catalyzes the initial and rate-limiting step in the biosynthesis of ether lipids like plasmalogens by converting dihydroxyacetone phosphate (DHAP) to acyl-DHAP.
Biological function summary
GNPAT is essential in lipid biosynthesis since ether lipids are integral components of cell membranes and signaling molecules. The enzyme does not work in isolation; it forms part of a multi-enzyme complex that includes other important proteins like alkylglycerone phosphate synthase (AGPS). This association allows GNPAT to efficiently catalyze the first steps in the formation of plasmalogens which serve key roles in protecting cells from oxidative stress and in cell signaling.
Pathways
GNPAT functions efficiently within the ether lipid synthesis pathway which is critical for normal cellular membrane composition and function. The activity of GNPAT impacts the levels of plasmalogens influencing pathways involved in membrane dynamics and antioxidant defense. It works closely with AGPS enhancing the production of essential ether lipids and affects phospholipid metabolism interfacing indirectly with proteins involved in peroxisomal and mitochondrial functions.
GNPAT dysfunction has associations with rhizomelic chondrodysplasia punctata (RCDP) a genetic disorder characterized by skeletal abnormalities and developmental delay. The enzyme's interaction with proteins like Phospholipase A2 is relevant in understanding its role in RCDP. Additionally alterations in plasmalogen levels due to impaired GNPAT function are observed in neurological conditions such as Alzheimer's disease. This connection highlights the importance of GNPAT in maintaining normal brain lipid metabolism and preventing cognitive decline.
